文献速递临床试验与 GCP

左乙拉西坦或苯妥英急诊治疗儿童癫痫持续状态——EcLiPSE研究:随机对照试验研究方案

Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the EcLiPSE study: study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2017-06-19

EcLiPSE研究为IV期多中心平行组随机对照开放标签试验,纳入儿童惊厥性癫痫持续状态(CSE)经一线治疗仍有发作者,随机接受静脉苯妥英(20 mg/kg,最大2 g)或左乙拉西坦(40 mg/kg,最大2.5 g),主要结局为临床医生判定的CSE所有可见体征停止,计划每组140例、总样本308例。

要点

  • 儿童CSE二线治疗当前推荐静脉苯妥英,但缺乏证据且副作用明显。
  • 试验比较静脉苯妥英与左乙拉西坦作为二线治疗的有效性与安全性。
  • 主要结局为CSE所有可见体征停止,主要分析采用意向性治疗。

核心结论

  • 该试验将确定苯妥英或左乙拉西坦作为儿童CSE静脉二线药物哪个更有效,并为管理推荐提供证据,同时提供两者安全性的数据。

研究设计与样本

  • IV期、多中心、平行组、随机对照、开放标签试验。
  • 儿童CSE经一线治疗后仍有发作者随机接受静脉苯妥英20 mg/kg(最大2 g)或左乙拉西坦40 mg/kg(最大2.5 g)。
  • 每组140例、总样本308例随机并治疗参与者,按10%失访计算,每组140例有80%把握度检测CSE停止率从60%升至75%。
  • 患者入组时未获事先同意,后续在适当时机寻求家庭延迟同意,主要分析采用意向性治疗。

主要发现

  • 主要结局为治疗临床医生判定的CSE所有可见体征停止。
  • 次要结局包括因持续CSE需要进一步抗癫痫药物或快速序贯诱导、入住重症监护区域及严重不良反应。

关键数值与推荐

  • 苯妥英剂量20 mg/kg,最大2 g,静脉给药。
  • 左乙拉西坦剂量40 mg/kg,最大2.5 g,静脉给药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Convulsive status epilepticus (CSE) is the most common life-threatening neurological emergency in childhood. These children are also at risk of significant morbidity, with acute and chronic impact on the family and the health and social care systems. The current recommended first-choice, second-line treatment in children aged 6 months and above is intravenous phenytoin (fosphenytoin in the USA), although there is a lack of evidence for its use and it is associated with significant side effects. Emerging evidence suggests that intravenous levetiracetam may be effective as a second-line agent for CSE, and fewer adverse effects have been described. This trial therefore aims to determine whether intravenous phenytoin or levetiracetam is more effective, and safer, in treating childhood CSE. METHODS/DESIGN: This is a phase IV, multi-centre, parallel group, randomised controlled, open-label trial. Following treatment for CSE with first-line treatment, children with ongoing seizures are randomised to receive either phenytoin (20 mg/kg, maximum 2 g) or levetiracetam (40 mg/kg, maximum 2.5 g) intravenously. The primary outcome measure is the cessation of all visible signs of CSE as determined by the treating clinician. Secondary outcome measures include the need for further anti-seizure medications or rapid sequence induction for ongoing CSE, admission to critical care areas, and serious adverse reactions. Patients are recruited without prior consent, with deferred consent sought at an appropriate time for the family. The primary analysis will be by intention-to-treat. The primary outcome is a time to event outcome and a sample size of 140 participants in each group will have 80% power to detect an increase in CSE cessation rates from 60% to 75%. Our total sample size of 308 randomised and treated participants will allow for 10% loss to follow-up. DISCUSSION: This clinical trial will determine whether phenytoin or levetiracetam is more effective as an intravenous second-line agent for CSE, and provide evidence for management recommendations. In addition, this trial will also provide data on which of these therapies is safer in this setting. TRIAL REGISTRATION: ISRCTN identifier, ISRCTN22567894 . Registered on 27 August 2015 EudraCT identifier, 2014-002188-13 . Registered on 21 May 2014 NIHR HTA Grant: 12/127/134.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lyttle MD, Gamble C, Messahel S, et al. Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the EcLiPSE study: study protocol for a randomised controlled trial. Trials. 2017. PMID: 28629473. doi:10.1186/s13063-017-2010-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。